Tafinlar: Medgend

Tafinlar FDA Approved Drugs

TAFINLAR [Dabrafenib Mesylate^{C₂₃H₂₀F₃N₅O₂S₂CH₄O₃S}]

eq 50mg base (oral capsule)

eq 75mg base (oral capsule)

Novartis Pharms Corp^{May 29, 2013}

Tafinlar in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma.
Treatment of melanoma.
Treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.